Folic Acid Supplementation and Cardiac and Stroke Mortality among Hemodialysis Patients

Journal of Renal Nutrition

Volumn 20, Issue 5, 2010, Pages 293-302

  Leung, June ^a   Larive, Brett ^b   Dwyer, Johanna ^a,c,d   Hibberd, Patricia ^c   Jacques, Paul ^a,d   Rand, William ^c  

^a TUFTS UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; VITAMIN B COMPLEX;

ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEART DISEASE; HOSPITALIZATION; HUMAN; MALE; MALNUTRITION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; STROKE;

DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MALNUTRITION; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; STROKE; VITAMIN B COMPLEX;

EID: 77955834729     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.01.005     Document Type: Article

References (55)

1. USRDS 2002 annual data report 2002, United States Renal Data System, United States Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD.
2. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis 1998, 32:853-906.
3. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002, 39(Suppl 2):S1-S246. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board.
4. De Vecchi A.F., Bamonti-Catena F., Finazzi S., et al. Homocysteine, vitamin B12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients. Perit Dial Int 2000, 20:169-173.
5. Suliman M.E., Qureshi A.R., Barany P., et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000, 57:1727-1735.
6. Bostom A.G., Shemin D., Verhoef P., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997, 17:2554-2558.
7. Friedman A.N., Bostom A.G., Selhub J., et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001, 12:2181-2189.
8. Manns B.J., Burgess E.D., Hyndman M.E., et al. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end stage renal disease. Am J Kidney Dis 1998, 32:669-677.
9. Moustapha A., Gupta A., Robinson K., et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999, 55:1470-1475.
10. Bostom A.G., Shemin D., Lapane K.L., et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 1995, 114:93-103.
11. Rimm E.B., Willett W.C., Hu F.B., et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998, 279:359-364.
12. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-575.
13. Schnyder G., Roffi M., Flammer Y., et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart Study: A randomized controlled trial. JAMA 2002, 288:973-979.
14. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.
15. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
16. Albert C.M., Cook N.R., Gaziano J.M., et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. JAMA 2008, 299:2027-2036.
17. Ebbing M., Bleie O., Ueland P.M., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. JAMA 2008, 300:795-804.
18. Baker F., Picton D., Blackwood S. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: An outcome trial. Circulation 2002, 19:A3642.
19. Bazzano L.A., Reynolds K., Holder K.N., et al. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006, 296:2720-2726.
20. Wang X., Qin X., Demirtas H., et al. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet 2007, 369:1876-1882.
21. Peterson J.C., Spence J.D. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 1998, 351:263.
22. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Br Med J [Clin Res] 1998, 316:894-898. Homocysteine Lowering Trialists' Collaboration.
23. Brattstrom L., Israelsson B., Norrving B., et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990, 81:51-60.
24. Ubbink J.B., Vermaak W.J., van der Merwe A., et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994, 124:1927-1933.
25. Arnadottir M., Brattstrom L., Simonsen O., et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993, 40:236-240.
26. Hyndman M.E., Manns B.J., Snyder F.F., et al. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: A link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Metabolism 2003, 52:168-172.
27. Ziakka S., Rammos G., Kountouris S., et al. The effect of vitamin B6 and folate supplements on plasma homocysteine and serum lipids levels in patients on regular hemodialysis. Int Urol Nephrol 2001, 33:559-562.
28. Trimarchi H., Schiel A., Freixas E., et al. Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients. Nephron 2002, 91:58-63.
29. Dierkes J., Domrose U., Bosselmann K.P., et al. Homocysteine lowering effect of different multi-vitamin preparations in patients with end-stage renal disease. J Ren Nutr 2001, 11:67-72.
30. Stanford J.L., Molina H., Phillips J., et al. Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease. J Thorac Cardiovasc Surg 2000, 8:567-571.
31. Bostom A.G., Shemin D., Bagley P., et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000, 101:2829-2832.
32. Yango A., Shemin D., Hsu N., et al. Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 2001, 59:324-327.
33. Arnadottir M., Gudnason V., Hultberg B. Treatment with different doses of folic acid in haemodialysis patients: Effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 2000, 15:524-528.
34. Sunder-Plassmann G., Fodinger M., Buchmayer H., et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study. J Am Soc Nephrol 2000, 11:1106-1116.
35. Gonin J.M., Nguyen H., Gonin R., et al. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol 2003, 16:522-534.
36. Wrone E.M., Hornberger J.M., Zehnder J.L., et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004, 15:420-426.
37. Righetti M., Serbelloni P., Milani S., et al. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006, 24:379-386.
38. Zoungas S., McGrath B.P., Branley P., et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol 2006, 47:1108-1116.
39. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease. JAMA 2007, 298:1163-1170.
40. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002, 347:2010-2019.
41. Makoff R. Water-soluble vitamin status in patients with renal disease treated with hemodialysis or peritoneal dialysis. J Ren Nutr 1991, 1:56-73.
42. Makoff R. Vitamin replacement therapy in renal failure patients. Miner Electrolyte Metab 1999, 25:349-351.
43. Cheung A.K., Sarnak M.J., Yan G., et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 2004, 65:2380-2389.
44. Miskulin D.C., Athienites N.V., Yan G., et al. Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney Int 2001, 60:1498-1510.
45. Stenvinkel P., Heimbürger O., Lindholm B., et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000, 15:953-960.
46. Stenvinkel P., Heimbürger O., Paultre F., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999, 55:1899-1911.
47. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990, 15:458-482.
48. Bergstrom J., Heimbürger O., Lindholm B., et al. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am Soc Nephrol 1995, 6:573.
49. Zimmermann J., Herrlinger S., Pruy A., et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
50. Ikizler T.A., Wingard R.L., Harvell J., et al. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int 1999, 55:1945-1951.
51. MacMahon M., Kirkpatrick C., Cummings C.E., et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000, 10:195-203.
52. The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 2002, 13:120-126. VITATOPS Trial Study Group.
53. Galan P., de Bree A., Mennen L., et al. Background and rationale of the SU.FOL.OM3 Study: Double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging 2003, 7:428-435.
54. Bostom A.G., Carpenter M.A., Kusek J.W., et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am Heart J 2006, 152:448.e1-448.e7.
55. Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials. Am Heart J 2006, 151:282-287. B Vitamin Treatment Trialists' Collaboration.